Dear Sir, The risk of diabetes is higher in patients with affected mothers than affected fathers. As the mitochondrial genome (mtDNA) is maternally inherited, a mitochondrial origin has been suspected. The mtDNA mutation that has been most frequently reported in diabetic patients is a A-to-G transition at nucleotide (nt) 3243 in the tRNA Leu(UUR) gene (for review Sherratt et al.) [1] . This mutation is found in about 1.5 % of the diabetic population in different countries and races, when mtDNA is extracted from leucocytes. Nevertheless this low percentage probably does not reflect the prevalence of mitochondrial gene mutations in diabetes. On the one hand, heteroplasmia is responsible for many false negative results and on the other, diabetes associated with mtDNA deletions or other mutations have been described [2] . For example, the nt 14 709 mutation is a T-to-C transition in the tRNA Glu gene that has been found in patients with diabetes mellitus and myopathy [3] . The pathogenicity of this mutation was suggested by several criteria : heteroplasmy, absence from control subjects, evolutionary conservation and correlation between the amount of mutant mtDNA and clinical severity.
We have investigated 140 diabetic patients, suspected of having a respiratory chain defect. The main clinical feature of mitochondrial diabetes is its near consistent association with others symptoms (e. g. deafness, neurological manifestations). The selection of patients depended on 2 types of clinical criteria : associated symptoms (81.4 %) or history of diabetes in maternal relatives (57.1 %) ( Table 1 ). Both criteria were found in 38.5 % of cases. In order to specify the role of various mtDNA abnormalities, all patients were screened both for mtDNA deletions and for point mutations at nt 3243 and nt 14 709. DNA was extracted from blood and amplified by ªlarge fragmentsº polymerase chain reaction (PCR) in order to detect mtDNA deletions [4] . The nt 3243 and nt 14 709 mutations were analysed by digestion of relevant PCR products with ApaI and NdeI restriction enzymes, respectively. We identified 8 patients with a nt 3243 mutation and 1 patient with a nt 14 709 mutation. All mutations were heteroplasmic. No mtDNA deletion was found. Accordingly, a mtDNA defect was detected in 9 patients (6.4 %), 6 of whom had a Type II diabetes mellitus, 2 a glucose intolerance and the last a Type I diabetes mellitus. All patients had other symptoms in association with the diabetes (8 of them had a sensory hearing disturbance). Only one patient (with a nt 3243 mutation) had no maternal history. In the group of 131 patients with no mtDNA abnormality detected in blood, a muscle biopsy was performed in 12 cases. The mitochondrial DNA extracted from muscular tissue was also analysed both for deletions and for the 2 mutations. A nt 3243 mutation was detected in a female who had deafness with a maternal history of diabetes. Ragged-red fibers were also found on muscular biopsy, despite the absence of a clinical myopathy. In our experience, the amount of mutant mtDNA is always higher in muscle than in blood cells, even when diabetic patients have no clinical muscular involvement [5, 6] .
In our study, the percentage of mtDNA abnormalities detected in blood is higher than in other reports (6.4 % vs about 1.5 %) because we selected patients on clinical criteria (associated symptoms and maternal transmission of diabetes). We have found a mtDNA defect in 10.5 % of patients who had diabetes in combination with deafness. This high percentage confirms previous reports indicating that the prevalence of the 3243 nt mutation is increased in diabetic populations with sensory hearing loss [7, 8] . Until now, mitochondrial diabetes has probably been underestimated because of heteroplasmy and difficulty of searching for all mutations in the mitochondrial genome for each patient, despite the use of different techniques [9] . Moroever, it is likely that in some families, mitochondrial diabetes is secondary to mutations in nuclear genes coding for proteins belonging to the respiratory chain or important for the stability of the mitochondrial genome.
In conclusion, these results demonstrate that clinical criteria are most important to improve the detection of diabetes secondary to a respiratory chain defect. A mitochondrial origin might be evocated when diabetes is associated with other symptoms, especially with nerve deafness. Effect of angiotensin II and bradykinin on insulin-stimulated tyrosine kinase activity of insulin receptor Dear Sir, Sechi et al. reported that angiotensin II (AII) infusion and captopril treatment did not affect insulin receptor binding and mRNA levels in the rat kidney [1] . This observation is an interesting counter evidence against the suggested role for AII in the modulation of renal sensitivity to insulin [2, 3] . This animal study with renal insulin receptor, however, may not exclude the possibilities that: 1) AII may modulate the post-receptor transignalling steps; 2) rat kidney may not be the most ideal candidate organ for evaluating insulin action (sensitivity); and 3) one cannot exclude the possibility that modulation of the insulin sensitivity by captopril [4, 5] might also be mediated by kinin [5] . We, therefore, measured the insulin receptor tyrosine kinase activity, the key step of post-insulin receptor transignalling pathway, in human adipocytes to assess whether AII and bradykinin (BK) would enhance the insulin action. AII receptors have been shown to exist in rat [6, 7] and human adipocytes [6] .
Adipocytes from surgically removed fat tissue were incubated with insulin to activate the receptor tyrosine kinase, with and without the presence of AII and BK. We observed that insulin increased the insulin receptor tyrosine kinase activity, measured according to the method by Klein et al. [8] , in a dose-dependent manner (Fig. 1) . Meanwhile, neither AII nor BK had an influence on the insulin-stimulated tyrosine kinase activity, even at the maximum concentration applied: 0.46 (saline), 0.44 (AII) and 0.43 (BK)fmolP × fmol BA ±1 × min ±1 (Fig. 1 ). These observations suggest that AII and BK have no effect on the insulin-stimulated insulin receptor tyrosine kinase activity in human adipocytes. 
